Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “PARP Inhibitors”

304 trials

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 304 results

Testing effectiveness (Phase 2)Study completedNCT04740190
What this trial is testing

Talazoparib - Carboplatin for Recurrent High-grade Glioma With DDRd

Who this might be right for
Recurrent GliomaRecurrent GlioblastomaPoly ADP Ribose Polymerase (PARP) Inhibitor+2 more
The University of Hong Kong 33
Early research (Phase 1)Study completedNCT00516724
What this trial is testing

Study to Assess the Safety and Tolerability of a PARP Inhibitor in Combination With Carboplatin and/or Paclitaxel

Who this might be right for
Triple Negative Metastatic Breast CancerAdvanced Ovarian CancerCarboplatin+1 more
AstraZeneca 189
Testing effectiveness (Phase 2)Looking for participantsNCT04503265
What this trial is testing

A Trial of AMXI-5001 for Treatment in Patients With Advanced Malignancies

Who this might be right for
Advanced Malignant NeoplasmBreast CancerOvarian Cancer+3 more
AtlasMedx, Incorporated 122
Testing effectiveness (Phase 2)Active Not RecruitingNCT01081951
What this trial is testing

Study to Compare the Efficacy and Safety of Olaparib When Given in Combination With Carboplatin and Paclitaxel, Compared With Carboplatin and Paclitaxel in Patients With Advanced Ovarian Cancer

Who this might be right for
Ovarian Cancer
AstraZeneca 162
Not applicableActive Not RecruitingNCT07303218
What this trial is testing

The HER Project: HRD in EGFR-mutated NSCLC

Who this might be right for
EGFRNon Small Cell Lung CancerHomologous Recombination Deficiency+1 more
IRCCS San Raffaele 100
Post-approval studies (Phase 4)Looking for participantsNCT07695259
What this trial is testing

Olaparib+Trastuzumab+Pertuzumab Neoadjuvant for Elderly HER2+ Breast Cancer

Who this might be right for
Elderly FemalesHER2 + Breast CancerNeoadjuvant Therapy
Wen-Ming Cao 45
Not applicableUnknownNCT04782089
What this trial is testing

Study of PD-1 Antibody and PARP Inhibitor in Extensive Stage Small Cell Lung Cancer

Who this might be right for
Small Cell Lung Cancer
Qilu Hospital of Shandong University 20
Testing effectiveness (Phase 2)Study completedNCT03639935
What this trial is testing

Rucaparib in Combination With Nivolumab in Patients With Advanced or Metastatic Biliary Tract Cancer Following Platinum Therapy

Who this might be right for
Biliary Tract Cancer
University of Michigan Rogel Cancer Center 32
Early research (Phase 1)Study completedNCT00516438
What this trial is testing

Study to Assess the Safety and Tolerability of a PARP Inhibitor in Combination With Topotecan

Who this might be right for
Malignant Solid Tumors
AstraZeneca 48
Testing effectiveness (Phase 2)UnknownNCT01788332
What this trial is testing

Parp Inhibitor in Advanced Non-Small Cell Lung Cancer (PIN)

Who this might be right for
Non-small Cell Lung Cancer
Lisette Nixon 70
Early research (Phase 1)Study completedNCT00678132
What this trial is testing

AZD2281 and Cisplatin Plus Gemcitabine to Treat Solid Tumor Cancers

Who this might be right for
Neoplasms
National Cancer Institute (NCI) 23
Early research (Phase 1)Study completedNCT05002868
What this trial is testing

Safety, Pharmacokinetics and Anti-tumor Activity of RP12146, in Patients With Solid Tumors

Who this might be right for
Solid TumorExtensive-stage Small-cell Lung CancerLocally Advanced Breast Cancer+4 more
Rhizen Pharmaceuticals SA 23
Early research (Phase 1)Study completedNCT01247168
What this trial is testing

An Open-Label, Dose-Escalation Study of AZD2461

Who this might be right for
Refractory Solid TumorsCancer Tumor
AstraZeneca 75
Early research (Phase 1)Looking for participantsNCT06930755
What this trial is testing

Study of NMS-03305293 in Adult Patients With Relapsed Ovarian Cancer

Who this might be right for
Ovarian Cancer
Nerviano Medical Sciences 24
Testing effectiveness (Phase 2)Study completedNCT02042378
What this trial is testing

Rucaparib in Patients With Pancreatic Cancer and a Known Deleterious BRCA Mutation

Who this might be right for
Pancreatic CancerPancreatic Ductal Adenocarcinoma
pharmaand GmbH 19
Not applicableLooking for participantsNCT05242744
What this trial is testing

FTT PET/CT in Metastatic Prostate Cancer

Who this might be right for
Prostate Cancer Metastatic
Abramson Cancer Center at Penn Medicine 30
Early research (Phase 1)Looking for participantsNCT06931626
What this trial is testing

Study of NMS-03305293 in Adult Patient With Relapsed Small Cell Lung Cancer

Who this might be right for
Small Cell Lung Cancer
Nerviano Medical Sciences 10
Large-scale testing (Phase 3)Study completedNCT02163694
What this trial is testing

Randomized, Placebo-controlled Trial of Carboplatin and Paclitaxel With or Without Veliparib (ABT-888) in HER2-negative Metastatic or Locally Advanced Unresectable BRCA-associated Breast Cancer

Who this might be right for
Metastatic Breast Cancer
AbbVie 513
Testing effectiveness (Phase 2)Active Not RecruitingNCT03672773
What this trial is testing

Talazoparib and Low-Dose Temozolomide in Treating Participants With Relapsed or Refractory Extensive-Stage Small Cell Lung Cancer

Who this might be right for
Recurrent Extensive Stage Small Cell Lung CarcinomaRefractory Extensive Stage Small Cell Lung Carcinoma
Jonsson Comprehensive Cancer Center 35
Early research (Phase 1)WithdrawnNCT02686008
What this trial is testing

Pharmacodynamic Study to Assess the Anti-proliferative Activity of the PARP Inhibitor Olaparib in Patients With HPV Positive and HPV Negative HNSCC

Who this might be right for
Squamous Cell Carcinoma of the Head and Neck
Yale University
Next Page